# A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis

> **NCT03998683** · PHASE3 · COMPLETED · sponsor: **Janssen-Cilag Ltd.** · enrollment: 117 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Guselkumab 100 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03998683
- **Lead sponsor:** Janssen-Cilag Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-03
- **Primary completion:** 2021-03-02
- **Final completion:** 2021-11-30
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2022-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03998683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03998683, "A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03998683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*